Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: Practical aspects

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue SUPPL3, 2013, Pages

  Akan, Hamdi ^a   Antia, Vistasp P ^b   Kouba, Michal ^c   Sinkó, János ^d   Tǎnase, Alina Daniela ^e   Vrhovac, Radovan ^f   Herbrecht, Raoul ^g  

^a ANKARA UNIVERSITY   (Turkey)

^b BREACH CANDY HOSPITAL   (India)

^c INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^d Szent Laszlo Hospital   (Hungary)

^e FUNDENI CLINICAL INSTITUTE   (Romania)

^f KBC Zagreb   (Croatia)

^g HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Aspergillosis; Candidiasis; Haematological malignancy; Immunocompromised hosts; Prophylaxis

Indexed keywords

ALPRAZOLAM; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; ASTEMIZOLE; CISAPRIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; EFAVIRENZ; ERGOT ALKALOID; FLUCONAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; ITRACONAZOLE; MICAFUNGIN; MIDAZOLAM; NIFEDIPINE; OMEPRAZOLE; PHENYTOIN; POSACONAZOLE; PROTEIN TYROSINE KINASE INHIBITOR; PROTON PUMP INHIBITOR; QUINIDINE; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; TERFENADINE; TRIAZOLAM; UNINDEXED DRUG; VINCRISTINE; VORICONAZOLE; WARFARIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADRENAL CORTEX INSUFFICIENCY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLOOD CULTURE; BRAIN DISEASE; CANDIDIASIS; CHILL; CLINICAL PRACTICE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INTOLERANCE; GASTROINTESTINAL TOXICITY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GYNECOMASTIA; HAND WASHING; HEMATOLOGIC MALIGNANCY; HOSPITAL HYGIENE; HUMAN; HYPOKALEMIA; IMAGING AND DISPLAY; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LIVER FUNCTION; LIVER TOXICITY; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; LUNG INFILTRATE; LUNG LAVAGE; MOULD; MUCOCUTANEOUS CANDIDIASIS; MUCORMYCOSIS; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NOSOCOMIAL CANDIDIASIS; PRACTICE GUIDELINE; RASH; REDUCED INTENSITY CONDITIONING; RIGOR; RISK ASSESSMENT; SIDE EFFECT; SKIN CANCER; SYSTEMIC MYCOSIS; TERATOGENICITY; TREATMENT DURATION; TREATMENT OUTCOME; VISION;

ASPERGILLOSIS; CANDIDIASIS; HAEMATOLOGICAL MALIGNANCY; IMMUNOCOMPROMISED HOSTS; PROPHYLAXIS;

ANTIFUNGAL AGENTS; CASE MANAGEMENT; CHEMOPREVENTION; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; INDIVIDUALIZED MEDICINE; MYCOSES; RISK ASSESSMENT; TRANSPLANTATION, HOMOLOGOUS;

EID: 84886616306     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt389     Document Type: Article

References (104)

1. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
2. Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001- 2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091-100.
3. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-75.
4. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
5. Wingard JR. Antifungal chemoprophylaxis after blood and marrow transplantation. Clin Infect Dis 2002; 34: 1386-90.
6. Marks DI, Pagliuca A, Kibbler CC et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 2011; 155: 318-27.
7. Dolton MJ, Ray JE, Chen SC et al. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother 2012; 56: 5503-10.
8. Peterson L, Ostermann J, Rieger H et al. Posaconazole prophylaxis- impact on incidence of invasive fungal disease and antifungal treatment in haematological patients. Mycoses 2013; doi:10.1111/myc.12086.
9. Vehreschild JJ, Ruping MJ, Wisplinghoff H et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother 2010; 65: 1466-71.
10. Ruping MJ, Vehreschild JJ, Cornely OA. Patients at high risk of invasive fungal infections: when and how to treat. Drugs 2008; 68: 1941-62.
11. Cordonnier C, Pautas C, Maury S et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48: 1042-51.
12. Caira M, Girmenia C, Fadda RM et al. Invasivefungal infections inpatients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk? Eur J Haematol 2008; 81: 242-3.
13. Martino R, Subira M. Invasive fungal infections in hematology: new trends. Ann Hematol 2002; 81: 233-43.
14. Pagano L, Akova M, Dimopoulos G et al. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother 2011; 66 Suppl 1: i5-14.
15. Rickerts V, Bohme A, Just-Nubling G. Risk factor for invasive zygomycosis in patients with hematologic malignancies. Mycoses 2002; 45 Suppl 1: 27-30.
16. Maertens J, Marchetti O, Herbrecht R et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2011; 46: 709-18.
17. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
18. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: e56-93.
19. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
20. Worth LJ, Slavin MA. Bloodstream infections in haematology: risks and new challenges for prevention. Blood Rev 2009; 23: 113-22.
21. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47.
22. Schwartz S, Ruhnke M, Ribaud P et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: 2641-5.
23. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-33.
24. Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705-13.
25. Robenshtok E, Gafter-Gvili A, Goldberg E et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 25: 5471-89.
26. Hachem R, Sumoza D, Hanna H et al. Clinical and radiologic predictors of invasive pulmonary aspergillosis in cancer patients: should the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria be revised? Cancer 2006; 106: 1581-6.
27. Zhang P, Jiang EL, Yang DL et al. Risk factors and prognosis of invasive fungal infections in allogeneic stem cell transplantation recipients: a single-institution experience. Transpl Infect Dis 2010; 12: 316-21.
28. Montagna MT, De Giglio O, Napoli C et al. Invasive fungal infections in patients with hematologic malignancies (AURORA Project): lights and shadows during 18-months surveillance. Int J Mol Sci 2012; 13: 774-87.
29. Lewis RE, Cahyame-Zuniga L, Leventakos K et al. Epidemiologyand sites of involvementof invasive fungal infections in patients withhaematological malignancies: a 20-year autopsy study. Mycoses 2013; doi:10.1111/ myc.12081.
30. Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol 2007; 139: 519-31.
31. BodeyGP. Infectious complications of acute leukemia.MedTimes 1966; 94: 1076-85.
32. Portugal RD, Garnica M, Nucci M. Index to predict invasivemoldinfection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol 2009; 27: 3849-54.
33. Garcia-Vidal C, Upton A, Kirby KA et al. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47: 1041-50.
34. Panackal AA, Li H, Kontoyiannis DP et al. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis 2010; 50: 1588-97.
35. Blum G, Eschertzhuber S, Auberger J et al. Airborne fungus exposure prior to hospitalisation as risk factor for mould infections in immunocompromised patients. Mycoses 2012; 55: 237-43.
36. Munoz P, Burillo A, Bouza E. Environmental surveillance and other control measures in the prevention of nosocomial fungal infections. Clin Microbiol Infect 2001; 7 Suppl 2: 38-45.
37. Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-61.
38. Slavin MA, Heath CH, Thursky KA et al. Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy. Intern Med J 2008; 38: 468-76.
39. Thursky K, Byrnes G, Grigg A et al. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transpl 2004; 34: 115-21.
40. Bow EJ. Long-term antifungal prophylaxis in high-risk hematopoietic stem cell transplant recipients. Med Mycol 2005; 43 Suppl 1: S277-87.
41. Gubbins PO, Amsden JR. Drug-drug interactions of antifungal agents and implications for patient care. Expert Opin Pharmacother 2005; 6: 2231-43.
42. Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 2013; 73: 919-34.
43. Bruggemann RJ, Alffenaar JW, Blijlevens NM et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 1441-58.
44. Wang EJ, Lew K, Casciano CN et al. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 2002; 46: 160-5.
45. Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy 2010; 30: 842-54.
46. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26: 1730-44.
47. Elbey MA, Cil H, Onturk E et al. QTc prolongation and torsade de pointes ventricular tachycardia in a small dose voriconazole therapy. Eur Rev Med Pharmacol Sci 2012; 16: 100-2.
48. Girmenia C, Iori AP. Safety and interactions of new antifungals in stem cell transplant recipients. Expert Opin Drug Saf 2012; 11: 803-18.
49. Buggia I, Zecca M, Alessandrino EP et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 1996; 16: 2083-8.
50. Moriyama B, Henning SA, Leung J et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses 2012; 55: 290-7.
51. van Schie RM, Bruggemann RJ, Hoogerbrugge PM et al. Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia. J Antimicrob Chemother 2011; 66: 1853-6.
52. Wingard JR, Carter SL, Walsh TJ et al. Blood and Marrow Transplant Clinical Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116: 5111-8.
53. Nivoix Y, Leveque D, Herbrecht Ret al. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008; 47: 779-92.
54. Park WB, Kim NH, Kim KH et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012; 55: 1080-7.
55. Racil Z, Winterova J, Kouba M et al. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. Mycoses 2012; 55: 483-92.
56. Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 2011; 71: 11-41.
57. van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-16.
58. Alexander BD, Dodds Ashley ES, Addison RM et al. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2006; 8: 13-20.
59. Rijnders BJ, Cornelissen JJ, Slobbe L et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46: 1401-8.
60. Ullmann AJ, Akova M, Herbrecht R et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 2012; 18 Suppl 7: 53-67.
61. Pascual A, Calandra T, Bolay S et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-11.
62. Ananda-Rajah MR, Grigg A, Slavin MA. Making sense of posaconazole therapeutic drug monitoring: a practical approach. Curr Opin Infect Dis 2012; 25: 605-11.
63. Neubauer WC, Engelhardt M, KonigA et al. Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method. Antimicrob Agents Chemother 2010; 54: 4029-32.
64. Pasqualotto AC, Denning DW. Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance. Int J Antimicrob Agents 2007; 30: 93-4.
65. Purkins L,Wood N, Greenhalgh K et al. The pharmacokinetics and safety of intravenous voriconazole-a novel wide-spectrum antifungal agent. Br J Clin Pharmacol 2003; 56 Suppl 1: 2-9.
66. Howard A, Hoffman J, Sheth A. Application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother 2008; 42: 1859-64.
67. Denning D, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71.
68. Ullmann AJ, Cornely OA, Burchardt A et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50: 658-66.
69. Tonini J, Thiebaut A, Jourdil JF et al. Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease. Antimicrob Agents Chemother 2012; 56: 5247-52.
70. Berenguer J, Ali NM, Allende MC et al. Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother 1994; 38: 1303-8.
71. Glasmacher A, Hahn C, Leutner C et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42: 443-51.
72. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42: 1417-27.
73. Maaroufli Y, DeBruyne JM, Duchteau V et al. Early detection and identification of commonly encountered Candida species from simulated blood cultures by using a real-time PCR-based assay. J Mol Diagn 2004; 6: 108-14.
74. Morrissey CO, Chen SC, Sorrell TC et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis 2013; 13: 519-28.
75. Herbrecht R, Bories P, Moulin JC et al. Risk stratification for invasive aspergillosis in immunocompromised patients. Ann NY Acad Sci 2012; 1272: 23-30.
76. Marr KA, Balajee SA, McLaughlin L et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641-9.
77. Maertens J, Buve K, Anaissie E. Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: counterpoint. J Natl Compr Canc Netw 2008; 6: 183-9.
78. Skiada A, Lanternier F, Groll AH et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 2013; 98: 492-504.
79. Ruping MJ, Heinz WJ, Kindo AJ et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010; 65: 296-302.
80. Pang KA, Godet C, Fekkar A et al. Breakthrough invasive mould infections in patients treated with caspofungin. J Infect 2012; 64: 424-9.
81. Robertson MJ, Larson RA. Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy. Am J Med 1988; 84: 233-9.
82. Offner F, Cordonnier C, Ljungman P et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998; 26: 1098-103.
83. Grigg A, Slavin M. Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy. Transpl Infect Dis 2008; 10: 3-12.
84. Cornely OA, Bohme A, Reichert D et al. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother 2008; 61: 939-46.
85. Bjerke JW, Meyers JD, Bowden RA. Hepatosplenic candidiasis-a contraindication to marrow transplantation? Blood 1994; 84: 2811-4.
86. Nosari A, Ravini M, Cairoli R et al. Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia. Bone Marrow Transplant 2007; 39: 631-5.
87. Martino R, Parody R, Fukuda T et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious DiseasesWorking Party of the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 2928-36.
88. Allinson K, Kolve H, Gumbinger HG et al. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J Antimicrob Chemother 2008; 61: 734-42.
89. Mele L, Pagano L, Equitani F et al. Case reports. Secondary prophylaxis with liposomal amphotericin B after invasive aspergillosis following treatment for haematological malignancy. Mycoses 2001; 44: 201-3.
90. deFabritiis P, Spagnoli A, DiBartolomeo P et al. Efficacyof caspofunginas secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplant 2007; 40: 245-9.
91. Cordonnier C, Maury S, Pautas C et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33: 943-8.
92. Tomblyn M, Chiller T, Einsele H et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143-238.
93. Cordonnier C, Rovira M, Maertens J et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010; 95: 1762-8.
94. Mousset S, Hermann S, Klein SA et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 2005; 84: 734-41.
95. Marr KA, Laverdiere M, Gugel A et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40: 1762-9.
96. Reinwald M, Hummel M, Kovalevskaya E. Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. J Antimicrob Chemother 2012; 67: 2260-7.
97. Sanchez V, Vazquez JA, Barth-Jones D et al. Nosocomial acquisition of Candida parapsilosis: an epidemiologic study. Am J Med 1993; 94: 577-82.
98. Asmundsdottir LR, Erlendsdottir H, Haraldsson G et al. Molecular epidemiology of candidemia: evidence of clusters of smoldering nosocomial infections. Clin Infect Dis 2008; 47: e17-24.
99. O'Grady NP, Alexander M, Dellinger EPet al. Guidelines for the prevention of intravascular catheter-related infections. The Hospital Infection Control Practices Advisory Committee, Center for Disease Control and Prevention, US. Pediatrics 2002; 110: e51.
100. Kainer MA, Reagan DR, Nguyen DB et al. Fungal infections associated with contaminated methylprednisolone in Tennessee. N Engl J Med 2012; 367: 2194-203.
101. Sehulster L, Chinn RY. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003; 52: 1-42.
102. Lee LD, Berkheiser M, Jiang Y et al. Risk of bioaerosol contamination with Aspergillus species before and after cleaning in rooms filtered with high-efficiency particulate air filters that house patients with hematologic malignancy. Infect Control Hosp Epidemiol 2007; 28: 1066-70.
103. Tablan OC, Anderson LJ, Besser R et al. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004; 53: 1-36.
104. Benet T, Nicolle MC, Thiebaut A et al. Reduction of invasive aspergillosis incidence among immunocompromised patients after control of environmental exposure. Clin Infect Dis 2007; 45: 682-6.